Clinical Trials

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01774630 2026-05-26

NiloPost-STIM

31 enrolled

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04449549 2026-05-22

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

82 enrolled

Neoplasms

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

40 enrolled

Neoplasm Metastasis

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04626024 2026-05-04

TOKIN

17 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03784014 2026-04-29

MULTISARC

Phase 3 Completed

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02379416 2026-04-21

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

47 enrolled

Neoplasms

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

104 enrolled 33 charts

Phase 3 Active not recruiting

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Other hematologic neoplasm

40 enrolled

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT03874858 2026-04-02

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT07413263 2026-02-18

Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

Not yet recruiting

75 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

30 enrolled

Dermatologic

Melanoma

NCT00756509 2026-01-20

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Phase 4 Completed

34 enrolled 11 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

23 enrolled

Sarcoma

Chordoma

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Other hematologic neoplasm

81 enrolled 20 charts

Leukemia, Myeloid, Chronic-Phase

NCT01316250 2025-10-02

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Phase NA Completed

13 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02201459 2025-10-02

PETALs

Phase 3 Completed

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02917720 2025-09-22

NAUT

75 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07138378 2025-08-22

XS003-11

128 enrolled

Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Neoplasm Metastasis

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

51 enrolled

Other hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07091019 2025-07-29

ASC4REAL-2

Not yet recruiting

1,000 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT06409936 2025-07-08

PEARL

160 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

11 enrolled 9 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT01860456 2025-06-05

TIKlet

Completed

412 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled